- Conditions
- Concussion, Mild
- Interventions
- Pro2Cool Device, Sham Cooling Garment Device
- Device
- Lead sponsor
- TecTraum Inc.
- Industry
- Eligibility
- 13 Years to 21 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 3
- States / cities
- Ann Arbor, Michigan • Akron, Ohio • Cleveland, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 889–912
of 3,311
matching trials from the local directory fallback.
- Conditions
- Burkitt Lymphoma, Follicular Lymphoma, Hairy Cell Leukemia, Large B-cell Lymphoma, Lymphoplasmacytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
- Interventions
- CD22CART Infusion
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 148 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Congenital Heart Disease (CHD)
- Interventions
- Umbilical Cord Clamping at ~120 seconds, Umbilical Cord Clamping at ~30 seconds, Umbilical Cord Milking
- Procedure
- Lead sponsor
- Carl Backes, MD
- Other
- Eligibility
- 37 Weeks to 42 Weeks
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Los Angeles, California • Orange, California + 15 more
- Conditions
- Short Bowel Syndrome
- Interventions
- HM15912 Active, Placebo
- Drug
- Lead sponsor
- Hanmi Pharmaceutical Company Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Cleveland, Ohio
- Conditions
- AML (Acute Myeloid Leukemia), Cholangiocarcinoma, Glioma, Solid Tumor Malignancies
- Interventions
- CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe Substrates, Olutasidenib
- Drug
- Lead sponsor
- Rigel Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- Orange, California • New York, New York
- Conditions
- Sarcoma,Soft Tissue
- Interventions
- Eribulin, INT230-6, Pazopanib, Trabectedin
- Drug
- Lead sponsor
- Intensity Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 333 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Santa Monica, California • New Haven, Connecticut + 5 more
- Conditions
- Abdominal Neoplasm, Advanced Solid Tumors, Carcinoma, Colorectal Cancer, Epstein-Barr Virus Infections, Genital Neoplasm, Female, Lung Neoplasm, NSCLC (Non-small Cell Lung Cancer), Neoplasms, Neoplasms by Site, Papillomavirus Infection, Urogenital Neoplasms, Vulvar Diseases, Vulvar Neoplasms
- Interventions
- Docetaxel (Taxotere), Irinotecan (Camptosar), STAR0602
- Combination Product · Drug
- Lead sponsor
- Marengo Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 366 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 13
- States / cities
- Sacramento, California • Celebration, Florida • Miami, Florida + 10 more
- Conditions
- Bipolar Disorder I, Bipolar Disorder II, Schizo-Affective Disorder, Schizophrenia, Schizophreniform; Schizophrenic
- Interventions
- BXCL501 120 Micrograms, BXCL501 60 Micrograms, BXCL501 80 Micrograms, Placebo Film
- Drug
- Lead sponsor
- BioXcel Therapeutics Inc
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 5
- States / cities
- Anaheim, California • Hialeah, Florida • Atlanta, Georgia + 2 more
- Conditions
- T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, T-non-Hodgkin Lymphoma
- Interventions
- Allogeneic CD5.CAR/28zeta CAR T cells, Autologous CD5.CAR/28zeta CAR T cells
- Genetic
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Up to 75 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2040
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Hip Pain, Hip Pain Chronic, Physical Medicine and Rehabilitation
- Interventions
- HIPS-1, HIPS-2
- Behavioral
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Nonintubated Acute Respiratory Distress Syndrome (ARDS), Pathogen-associated Lung Injury
- Interventions
- Placebo, Vadadustat 1200mg, Vadadustat 900mg
- Drug
- Lead sponsor
- Paul Potnuru
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Parkinson's Disease
- Interventions
- [18F]PI-2620
- Drug
- Lead sponsor
- Michael J. Fox Foundation for Parkinson's Research
- Other
- Eligibility
- 45 Years to 85 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- HR+, HER2-, Advanced Breast Cancer, HR+/HER2- Breast Cancer
- Interventions
- AVZO-021, AVZO-023, Fulvestrant, Letrozole
- Drug
- Lead sponsor
- Avenzo Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 380 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 16
- States / cities
- Los Angeles, California • New Haven, Connecticut • Orlando, Florida + 12 more
- Conditions
- Hematologic Malignancies, Solid Malignancies
- Interventions
- IM-1021
- Drug
- Lead sponsor
- Immunome, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 19
- States / cities
- Duarte, California • Los Angeles, California • Denver, Colorado + 16 more
- Conditions
- Geographic Atrophy Secondary to Age-related Macular Degeneration
- Interventions
- VV-14295
- Genetic
- Lead sponsor
- Kriya Therapeutics, Inc.
- Industry
- Eligibility
- 55 Years to 80 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Erie, Pennsylvania
- Conditions
- Fabry Disease
- Interventions
- PRX-102 1 mg/kg every two weeks
- Drug
- Lead sponsor
- Chiesi Farmaceutici S.p.A.
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Atlanta, Georgia • Iowa City, Iowa + 3 more
- Conditions
- HIV Infections
- Interventions
- Oral VH4524184, Placebo Formulation A IM, Placebo Formulation A SC, Placebo Formulation B IM, Placebo Formulation B SC, VH4524184 Formulation A IM, VH4524184 Formulation A SC, VH4524184 Formulation B IM, VH4524184 Formulation B SC, rHuPH20
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 372 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2028
- U.S. locations
- 3
- States / cities
- Lenexa, Kansas • San Antonio, Texas • Salt Lake City, Utah
- Conditions
- Multiple Myeloma
- Interventions
- BCMA-TGFβ CAR-T cells (0.50 x 10^6 cells/kg), BCMA-TGFβ CAR-T cells (0.75 x10^6 cells/kg), BCMA-TGFβ CAR-T cells (1 x 10^6 cells/kg), BCMA-TGFβ CAR-T cells (2.5 x 10^6 cells/kg), Maximum tolerated dose
- Biological
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Low Risk Myelodysplastic Syndromes
- Interventions
- R906289 Monosodium (R289 Na)
- Drug
- Lead sponsor
- Rigel Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 15
- States / cities
- Los Angeles, California • Orange, California • Palo Alto, California + 12 more
- Conditions
- Hydrocephalus, Intracerebral Hemorrhage, Subarachnoid Hemorrhage, Ventriculitis, Cerebral
- Interventions
- 24 hours antibiotics, Long term (continuous) prophylactic antibiotics
- Drug
- Lead sponsor
- Montefiore Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Pulmonary Arterial Hypertension, Pulmonary Hypertension
- Interventions
- 129Xe Hyperpolarized
- Drug
- Lead sponsor
- Bastiaan Driehuys
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- The Focus of This Study is to Collect OCT Data on Normal Eyes
- Interventions
- OCT device called VG200D
- Device
- Lead sponsor
- Intalight, Inc
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 350 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 3
- States / cities
- San Diego, California • Chicago, Illinois • Bloomington, Indiana
- Conditions
- Glioblastoma Multiforme (GBM), Pancreatic Ductal Adenocarcinoma (PDAC)
- Interventions
- 203Pb-RMX-VHPIB injection, SPECT/CT Imaging
- Drug · Diagnostic Test
- Lead sponsor
- Radiomedix, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- COVID-19 Vaccines
- Interventions
- BNT162b2 Vaccine, Tdap Vaccine
- Biological
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 5
- States / cities
- Walnut Creek, California • Miami Lakes, Florida • Honolulu, Hawaii + 2 more